Sarah Hellenbrand, OTR Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 80 1st St, Prairie Du Sac, WI 53578 Phone: 608-643-3311 |
Mrs. Margaret Owen Faludi, OTR Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 80 1st St, Prairie Du Sac, WI 53578 Phone: 608-643-7263 Fax: 608-643-7667 |
Elizabeth Christine Deroche, OTR/L Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 90 Oak St, Prairie Du Sac, WI 53578 Phone: 608-643-7145 |
Kelly Chernik, OTR Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 90 Oak St, Prairie Du Sac, WI 53578 Phone: 608-643-7263 |
Diane Austin, OTR Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 80 1st St, Prairie Du Sac, WI 53578 Phone: 608-643-7263 Fax: 608-643-7667 |
Brittany Thompson, OTR Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 260 26th St, Prairie Du Sac, WI 53578 Phone: 608-643-7263 |
Ms. Melissa Jean Acker, OTR Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 80 1st St, Prairie Du Sac, WI 53578 Phone: 608-643-7263 |
News Archive
A small piece of RNA appears to play a big role in the development of idiopathic pulmonary fibrosis (IPF), according to lung disease researchers at the University of Pittsburgh School of Medicine. Their study, which is the first to examine microRNAs in the disease, is available online in the American Journal of Respiratory and Critical Care Medicine.
Even the least graceful among us has motor control the most high-tech unmanned undersea vehicle would envy, thanks to a region of the brain that allows our bodies to carry out complex maneuvers. The Office of Naval Research, which traditionally relies on the power of the human mind to achieve breakthroughs in science and technology, now also is harnessing the working principle of the brain to control the maneuvers of UUVs.
Hospital admissions for cardiovascular diseases increased during the Greek financial crisis, according to two studies from Athens. The research was presented today at the Heart Failure Congress 2014, held 17-20 May in Athens, Greece.
In a first-time disclosure of IPN60090, a small-molecule inhibitor of the metabolic enzyme glutaminase (GLS1), researchers from The University of Texas MD Anderson Cancer Center's Therapeutics Discovery division and Ipsen Biopharmaceuticals reported the preclinical discovery and early-stage clinical development of this novel drug. IPN60090, now under investigation in a Phase I trial, may hold benefit for certain patients with lung and ovarian cancers.
› Verified 9 days ago